Al Sandrock, Voyager Therapeutics CEO
Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine
The neurological disease outfit helmed by Biogen’s former R&D chief announced a big gene therapy deal Monday, starting #JPM23 with its largest deal to date …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.